Poth Professor of Cutaneous Oncology
Associate Chair
Department of Dermatology
Professor of Dermatology
Professor of Cell and Developmental Biology
[email protected]
Available to mentor
Andrzej Dlugosz, MD
Professor
-
MDPennsylvania State University College of Medicine, USA
-
Center MemberCenter for Cell Plasticity and Organ Design
-
Center MemberRogel Cancer Center
-
Sun L, Verhaegen ME, McGue J, Olivei AC, Dlugosz AA, Frankel TL, Harms PW. Lab Invest, 2024 Oct; 104 (10): 102128Journal ArticleDevelopment of a Multiplex Immunofluorescence Assay for Tumor Microenvironment Studies of Human and Murine Merkel Cell Carcinoma.
DOI:10.1016/j.labinv.2024.102128 PMID: 39182611 -
Choi JE, Verhaegen ME, Yazdani S, Malik R, Harms PW, Mangelberger D, Tien J, Cao X, Wang Y, Cieślik M, Gurkan J, Yazdani M, Jing X, Juckette K, Su F, Wang R, Zhou B, Apel IJ, Wang S, Dlugosz AA, Chinnaiyan AM. Neoplasia, 2024 Sep; 55: 101019Journal ArticleCorrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330].
DOI:10.1016/j.neo.2024.101019 PMID: 38943995 -
Zhu X, Xu M, Portal C, Lin Y, Ferdinand A, Peng T, Morrisey EE, Dlugosz AA, Castellano JM, Lee V, Seykora JT, Iomini C, Millar SE. bioRxiv, 2024 Aug 10;Journal ArticleIdentification of Meibomian gland stem cell populations and mechanisms of aging.
DOI:10.1101/2024.08.09.607015 PMID: 39149265 -
van Drongelen V, Young K, Gharaee-Kermani M, Plazyo O, Griffin E, Syu L, Xing E, Ward NL, Tsoi LC, Kahlenberg M, Dlugosz A, Gudjonsson JE, Billi A. Journal of Investigative Dermatology, 2024 May; 144 (8): s3 - s3.Proceeding / Abstract / Poster016 Investigating therapeutic targeting of the female-biased factor VGLL3 in lupus
DOI:10.1016/j.jid.2024.06.032 -
Verhaegen M, Singer K, Wilbert D, Moore A, Baumbick M, Walter E, Harms PW, Dlugosz A. Journal of Investigative Dermatology, 2024 Aug; 144 (8): s146Journal Article838 Immunotherapy-responsive preclinical model of Merkel cell carcinoma in immune-competent mice
DOI:10.1016/j.jid.2024.06.854 -
Meyer-Schuman R, Cale AR, Pierluissi JA, Jonatzke KE, Park YN, Lenk GM, Oprescu SN, Grachtchouk MA, Dlugosz AA, Beg AA, Meisler MH, Antonellis A. HGG Adv, 2024 Jul 18; 5 (3): 100324Journal ArticleA model organism pipeline provides insight into the clinical heterogeneity of TARS1 loss-of-function variants.
DOI:10.1016/j.xhgg.2024.100324 PMID: 38956874 -
Choi JE, Verhaegen ME, Yazdani S, Malik R, Harms PW, Mangelberger D, Tien J, Cao X, Wang Y, Cieślik M, Gurkan J, Yazdani M, Jing X, Juckette K, Su F, Wang R, Zhou B, Apel IJ, Wang S, Dlugosz AA, Chinnaiyan AM. Neoplasia, 2024 May; 51: 100995Journal ArticleCorrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330].
DOI:10.1016/j.neo.2024.100995 PMID: 38574506 -
Meyer-Schuman R, Cale AR, Pierluissi JA, Jonatzke KE, Park YN, Lenk GM, Oprescu SN, Grachtchouk MA, Dlugosz AA, Beg AA, Meisler MH, Antonellis A. 2024 Mar 27;PreprintPredictive modeling provides insight into the clinical heterogeneity associated with TARS1 loss-of-function mutations.
DOI:10.1101/2024.03.25.586600 PMID: 38585737